<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265459</url>
  </required_header>
  <id_info>
    <org_study_id>35GA1001</org_study_id>
    <nct_id>NCT01265459</nct_id>
  </id_info>
  <brief_title>Different Volumes of Durolane in Knee OA</brief_title>
  <official_title>Double-Blind, Randomized Study of Three Different Volumes of Durolane in Subjects With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and efficacy profiles of new
      single-injection volumes of Durolane in patients with knee OA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and efficacy profiles of different volumes of Durolane in patients with
      knee OA and compare with the current standard single-injection of the product. The study aims
      to investigate whether different volumes of Durolane compared to the standard injection
      volume will improve the benefit/risk profile.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Pain Over 26 Weeks (Change From Baseline)</measure>
    <time_frame>26 weeks after treatment compared to baseline</time_frame>
    <description>The study aims to compare the change of pain for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score that consists of 5 questions.
It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to how much pain the subject has experienced during the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability From Baseline to 26 Weeks After Treatment.</measure>
    <time_frame>From baseline to 26 weeks after treatment</time_frame>
    <description>Safety and tolerability will be assessed at each clinic visit (Baseline, 2, 6, 12, 18 and 26 weeks). Standard questions was used, &quot;Since your last clinical visit have you had any health problems?&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Stiffness Score (Change From Baseline)</measure>
    <time_frame>26 weeks after treatment compared to baseline</time_frame>
    <description>The study aims to compare the change of stiffness for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) stiffness score that consists of 2 questions.
It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to how much stiffness the subject has experienced in the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Physical Function Score (Change From Baseline)</measure>
    <time_frame>26 weeks after treatment compared to baseline</time_frame>
    <description>The study aims to compare the physical function for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) physical function score that consists of 17 questions.
It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to performing daily physical activities the subject has experienced in the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject´s Global Assessment of the Status of the Study Knee (Change From Baseline)</measure>
    <time_frame>26 weeks after treatment compared to baseline</time_frame>
    <description>The subject will assess his/her global status how the study knee affects them by using a 11-point numerical rating scale, Subject global assessment scale, from &quot;very poor=0&quot; to &quot;excellent=10&quot;.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Durolane 3ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durolane 3 ml is an Intraarticular hyaluronic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durolane 4.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durolane 4.5 is an Intraarticular hyaluronic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durolane 6 ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durolane 6 ml is an Intraarticular hyaluronic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml</intervention_name>
    <description>Durolane is an intraarticular hyaluronic acid preparation</description>
    <arm_group_label>Durolane 3ml</arm_group_label>
    <arm_group_label>Durolane 4.5</arm_group_label>
    <arm_group_label>Durolane 6 ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject (female or male)

          -  40-85 years of age

          -  Unilateral knee pain fulfilling American College of Rheumatology (ACR) criteria for
             diagnosis of osteoarthritis(OA)

          -  Radiographic evidence of OA in the study knee

          -  WOMAC pain score of 7-17 in the study knee

          -  WOMAC pain score of 2-3 in the study knee (WOMAC Likert 3.1 A1)

          -  Subject normally active

          -  Subject has attempted but not responded adequately to previous non-pharmacological
             therapy(ies)and to simple analgetics

          -  Subject cooperative and able to communicate effectively with the investigators

          -  Body mass index ≤ 35 kg/m2;

          -  Signed informed consent obtained

        Exclusion Criteria:

          -  Knee effusion

          -  Contralateral knee OA

          -  Clinically significant joint pain from joints other than the knee

          -  Previous intra-articular steroid injection into the study knee within the last 6
             months

          -  Previous intra-articular Hyaluronic Acid (HA) injection into the study knee within the
             last 9 months

          -  Previous allergic type reaction to a HA product

          -  Treatment with analgesics other than paracetamol (acetaminophen) (including topical
             agents for the knee) within 5 half lives of the drug prior to the baseline visit

          -  Use of analgesics 48 hours preceding the baseline visit

          -  Use of systemic glucocorticosteroids (excluding inhaled steroids) within the last 3
             months

          -  Treatment with glucosamine/chondroitin sulfate initiated within the past 3 months

          -  Change in physical therapy for the knee within the last three months

          -  Arthroscopy or other surgical procedure in the study knee within the past 12 months

          -  Serious injuries to the study knee in the past

          -  Any planned arthroscopy or other surgical procedure during the study period

          -  Previous history or presence of active septic arthritis

          -  Active skin disease or infection in the area of the injection site

          -  Systemic active inflammatory condition or infection

          -  Bleeding diathesis or use of anticoagulants

          -  History of drug or alcohol abuse within 6 months

          -  Any medical condition that in the opinion of the investigator makes the subject
             unsuitable for inclusion

          -  Pregnant or breastfeeding woman or woman of childbearing potential not practicing
             adequate contraception

          -  Involvement in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per-Erik Melberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kristinelundskliniken, Kristinelundsgatan 13, 411 37 Göteborg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Torsten Adalberth</name>
      <address>
        <city>Malmo</city>
        <zip>211 36</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Akermark</name>
      <address>
        <city>Stockholm</city>
        <zip>111 35</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johan Isacson</name>
      <address>
        <city>Upplands Vasby</city>
        <zip>194 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2010</study_first_posted>
  <results_first_submitted>December 3, 2013</results_first_submitted>
  <results_first_submitted_qc>December 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2014</results_first_posted>
  <last_update_submitted>March 17, 2014</last_update_submitted>
  <last_update_submitted_qc>March 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Durolane 3 mL</title>
          <description>Single injection of 3 ml Durolane (Durolane is an intraarticular hyaluronic acid preparation)</description>
        </group>
        <group group_id="P2">
          <title>Durolane 4.5 mL</title>
          <description>Single injection of 4.5 ml Durolane (Durolane is an intraarticular hyaluronic acid preparation)</description>
        </group>
        <group group_id="P3">
          <title>Durolane 6 mL</title>
          <description>Single injection of 6 ml Durolane (Durolane is an intraarticular hyaluronic acid preparation)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Durolane 3 mL</title>
          <description>Single injection of 3 ml Durolane (Durolane is an intraarticular hyaluronic acid preparation)</description>
        </group>
        <group group_id="B2">
          <title>Durolane 4.5 mL</title>
          <description>Single injection of 4.5 ml Durolane (Durolane is an intraarticular hyaluronic acid preparation)</description>
        </group>
        <group group_id="B3">
          <title>Durolane 6 mL</title>
          <description>Single injection of 6 ml Durolane (Durolane is an intraarticular hyaluronic acid preparation)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="9.8"/>
                    <measurement group_id="B2" value="64.1" spread="8.0"/>
                    <measurement group_id="B3" value="62.8" spread="7.3"/>
                    <measurement group_id="B4" value="63.1" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Pain Over 26 Weeks (Change From Baseline)</title>
        <description>The study aims to compare the change of pain for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score that consists of 5 questions.
It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to how much pain the subject has experienced during the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.</description>
        <time_frame>26 weeks after treatment compared to baseline</time_frame>
        <population>The primary population for all efficacy evaluations was the ITT population (all subjects randomized and treated with study product).
No imputation of missing data was done. Analyses presented were based on observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Durolane 3 mL</title>
            <description>WOMAC pain score at 26 weeks (change from baseline). Single intra-articular injection of Durolane (20mg/ml).</description>
          </group>
          <group group_id="O2">
            <title>Durolane 4.5 mL</title>
            <description>WOMAC pain score at 26 weeks (change from baseline). Single intra-articular injection of Durolane (20mg/ml).</description>
          </group>
          <group group_id="O3">
            <title>Durolane 6 mL</title>
            <description>WOMAC pain score at 26 weeks (change from baseline). Single intra-articular injection of Durolane (20mg/ml).</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Pain Over 26 Weeks (Change From Baseline)</title>
          <description>The study aims to compare the change of pain for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score that consists of 5 questions.
It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to how much pain the subject has experienced during the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.</description>
          <population>The primary population for all efficacy evaluations was the ITT population (all subjects randomized and treated with study product).
No imputation of missing data was done. Analyses presented were based on observed cases.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.13" spread="4.39"/>
                    <measurement group_id="O2" value="-4.00" spread="3.74"/>
                    <measurement group_id="O3" value="-4.90" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability From Baseline to 26 Weeks After Treatment.</title>
        <description>Safety and tolerability will be assessed at each clinic visit (Baseline, 2, 6, 12, 18 and 26 weeks). Standard questions was used, &quot;Since your last clinical visit have you had any health problems?”.</description>
        <time_frame>From baseline to 26 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Durolane 3 mL</title>
            <description>Single injection of 3 ml Durolane (Durolane is an intraarticular hyaluronic acid preparation)</description>
          </group>
          <group group_id="O2">
            <title>Durolane 4.5 mL</title>
            <description>Single injection of 4.5 ml Durolane (Durolane is an intraarticular hyaluronic acid preparation)</description>
          </group>
          <group group_id="O3">
            <title>Durolane 6 mL</title>
            <description>Single injection of 6 ml Durolane (Durolane is an intraarticular hyaluronic acid preparation)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability From Baseline to 26 Weeks After Treatment.</title>
          <description>Safety and tolerability will be assessed at each clinic visit (Baseline, 2, 6, 12, 18 and 26 weeks). Standard questions was used, &quot;Since your last clinical visit have you had any health problems?”.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Stiffness Score (Change From Baseline)</title>
        <description>The study aims to compare the change of stiffness for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) stiffness score that consists of 2 questions.
It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to how much stiffness the subject has experienced in the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.</description>
        <time_frame>26 weeks after treatment compared to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Durolane 3 mL</title>
            <description>WOMAC stiffness score at 26 weeks (change from baseline). Single injection of Durolane (20 mg/ml).</description>
          </group>
          <group group_id="O2">
            <title>Durolane 4.5 mL</title>
            <description>WOMAC stiffness score at 26 weeks (change from baseline). Single injection of Durolane (20 mg/ml).</description>
          </group>
          <group group_id="O3">
            <title>Durolane 6 mL</title>
            <description>WOMAC stiffness score at 26 weeks (change from baseline). Single injection of Durolane (20 mg/ml).</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Stiffness Score (Change From Baseline)</title>
          <description>The study aims to compare the change of stiffness for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) stiffness score that consists of 2 questions.
It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to how much stiffness the subject has experienced in the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="2.27"/>
                    <measurement group_id="O2" value="-1.39" spread="1.85"/>
                    <measurement group_id="O3" value="-1.15" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC Physical Function Score (Change From Baseline)</title>
        <description>The study aims to compare the physical function for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) physical function score that consists of 17 questions.
It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to performing daily physical activities the subject has experienced in the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.</description>
        <time_frame>26 weeks after treatment compared to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Durolane 3 mL</title>
            <description>WOMAC physical function score at 26 weeks (change from baseline). Single injection of Durolane (20 mg/ml).</description>
          </group>
          <group group_id="O2">
            <title>Durolane 4.5 mL</title>
            <description>WOMAC physical function score at 26 weeks (change from baseline). Single injection of Durolane (20 mg/ml).</description>
          </group>
          <group group_id="O3">
            <title>Durolane 6 mL</title>
            <description>WOMAC physical function score at 26 weeks (change from baseline). Single injection of Durolane (20 mg/ml).</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC Physical Function Score (Change From Baseline)</title>
          <description>The study aims to compare the physical function for different volumes of study product over 26 weeks using WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) physical function score that consists of 17 questions.
It is a 5-graded Likert scale: None, Mild, Moderate, Severe or Extreme relating to performing daily physical activities the subject has experienced in the last 48 hours. The score of each dimension is calculated by simply adding the score (from 0 to 4) for each question.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.14" spread="13.98"/>
                    <measurement group_id="O2" value="-13.13" spread="11.93"/>
                    <measurement group_id="O3" value="-12.32" spread="14.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject´s Global Assessment of the Status of the Study Knee (Change From Baseline)</title>
        <description>The subject will assess his/her global status how the study knee affects them by using a 11-point numerical rating scale, Subject global assessment scale, from &quot;very poor=0&quot; to &quot;excellent=10&quot;.</description>
        <time_frame>26 weeks after treatment compared to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Durolane 3 mL</title>
            <description>Subject´s global assessment of the status of the study knee at 26 weeks (change from baseline).
Single injection of Durolane (20 mg/ml).</description>
          </group>
          <group group_id="O2">
            <title>Durolane 4.5 mL</title>
            <description>Subject´s global assessment of the status of the study knee at 26 weeks (change from baseline).
Single injection of Durolane (20 mg/ml).</description>
          </group>
          <group group_id="O3">
            <title>Durolane 6 mL</title>
            <description>Subject´s global assessment of the status of the study knee at 26 weeks (change from baseline).
Single injection of Durolane (20 mg/ml).</description>
          </group>
        </group_list>
        <measure>
          <title>Subject´s Global Assessment of the Status of the Study Knee (Change From Baseline)</title>
          <description>The subject will assess his/her global status how the study knee affects them by using a 11-point numerical rating scale, Subject global assessment scale, from &quot;very poor=0&quot; to &quot;excellent=10&quot;.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="2.64"/>
                    <measurement group_id="O2" value="1.39" spread="2.44"/>
                    <measurement group_id="O3" value="1.70" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected during 26 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Durolane 3 mL</title>
          <description>Single injection of 3 ml Durolane (Durolane is an intraarticular hyaluronic acid preparation)</description>
        </group>
        <group group_id="E2">
          <title>Durolane 4.5 mL</title>
          <description>Single injection of 4.5 ml Durolane (Durolane is an intraarticular hyaluronic acid preparation)</description>
        </group>
        <group group_id="E3">
          <title>Durolane 6 mL</title>
          <description>Single injection of 6 ml Durolane (Durolane is an intraarticular hyaluronic acid preparation)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache and high fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Rectal prolaps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>The related arthralgia events had a rapid onset and usually started within 1 day after injection of the study product and the duration was in general short.</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Medical Affairs</name_or_title>
      <organization>Q-Med AB</organization>
      <phone>+46 (0) 18 4749000</phone>
      <email>reception.SEUPP@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

